サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1463246

ヘルスケア分析試験サービスの世界市場：市場規模 - タイプ別、エンドユーザー別、地域別 - 2029年までの予測

Healthcare Analytical Testing Services Market Size by Type, End User & Region - Global Forecast to 2029
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 393 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.85円
ヘルスケア分析試験サービスの世界市場：市場規模 - タイプ別、エンドユーザー別、地域別 - 2029年までの予測
出版日: 2024年04月10日
発行: MarketsandMarkets
ページ情報: 英文 393 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

ヘルスケア分析試験サービスの市場規模は、予測期間中に11.2%のCAGRで拡大し、2024年の74億米ドルから2029年には126億米ドルに達すると予測されています。

ヘルスケア分析試験サービス市場の成長は、品質保証と規制遵守に対する業界全体の需要の高まりによって促進されています。正確な分析技術の開発における課題がサービスプロバイダーに機会を提供する一方、政府の取り組みが投資と技術革新を後押ししています。これらの要因は、価格への懸念や革新的な医薬品の開発によるアウトソーシングなどの動向とともに、世界の市場拡大の原動力となっています。また、新たな場所への進出も特定の検査に対する需要を高め、ヘルスケア分析検査サービスのニーズをさらに促進しています。

調査範囲
調査対象年 2021年～2029年
基準年 2023年
予測期間 2024年～2029年
検討単位 金額（U10億米ドル）
セグメント タイプ別、エンドユーザー別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ

バイオヘルスケア分析試験サービスセグメントは、2023年に世界のヘルスケア分析試験サービス市場で37.1%の最大シェアを占めると予測されています。予測期間中のCAGRは10.7%と最も高く成長すると予測されています。ヘルスケア分析試験サービス市場は、バイオ分析試験、物理的特性評価、メソッド開発とバリデーション、安定性試験、バッチリリース試験、原材料試験、微生物試験、ゲノムサービス、環境モニタリングサービスなど、タイプ別にさまざまなカテゴリーに区分されます。2023年には、バイオヘルスケア分析試験サービス分野が最大で、主にワクチン、低分子化合物、生物製剤のようなさまざまな種類の医薬品に合わせた包括的なサービスを提供しています。この広範なサービスは、製薬企業やバイオ医薬品企業の多様な要件を満たすものであり、この分野の市場シェアを大きく押し上げる要因となっています。

バイオ分析サービスのタイプ別では、2023年には、セルベースアッセイ部門が市場リーダーに浮上しました。この優位性は、ハイスループット・スクリーニングにおいて、生化学的アッセイに比べてin vivoで適切な生物学的知見が得られる細胞ベースのアッセイが好まれるようになってきたことに起因します。この利点は創薬プロセスを加速させるため、このセグメントの優位性に寄与しています。

当レポートでは、世界のヘルスケア分析試験サービス市場について調査し、タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • エコシステム分析
  • バリューチェーン分析
  • ケーススタディ分析
  • ポーターのファイブフォース分析
  • 規制状況
  • 顧客のビジネスに影響を与える動向/混乱
  • 2024年～2025年の主な会議とイベント
  • 投資と資金調達のシナリオ
  • 主な利害関係者と購入基準

第6章 ヘルスケア分析試験サービス市場、タイプ別

  • イントロダクション
  • バイオ分析試験
  • 物理的特性
  • 方法の開発と検証
  • 原材料試験
  • バッチリリーステストサービス
  • 安定性テスト
  • 微生物検査
  • ゲノム検査サービス
  • その他

第7章 ヘルスケア分析試験サービス市場、エンドユーザー別

  • イントロダクション
  • 製薬会社
  • バイオ医薬品企業
  • 医療機器企業
  • 病院・クリニック
  • 法医学研究所
  • 化粧品・栄養補助食品会社

第8章 ヘルスケア分析試験サービス市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

  • イントロダクション
  • 主要参入企業が採用した勝者獲得のアプローチ
  • 収益分配分析
  • 市場シェア分析
  • 企業評価マトリックス：主要参入企業
  • 企業評価マトリックス：スタートアップ/中小企業
  • ヘルスケア分析検査サービスベンダーの評価と財務指標
  • ブランド/製品比較分析
  • 競合シナリオ

第10章 企業プロファイル

  • 主要参入企業
    • EUROFINS SCIENTIFIC
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • WUXI APPTEC
    • CHARLES RIVER LABORATORIES
    • SGS S.A.
    • THERMO FISHER SCIENTIFIC INC.
    • MEDPACE, INC.
    • SARTORIUS AG
    • INTERTEK GROUP PLC
    • MERCK KGAA
    • SOURCE BIOSCIENCE
    • ICON PLC
    • ALS
    • FRONTAGE LABORATORIES, INC.
    • STERIS
    • IQVIA INC.
    • ELEMENT MATERIALS TECHNOLOGY
    • PACE ANALYTICAL SERVICES
    • ALMAC GROUP
    • PHARMARON
  • その他の企業
    • SYNEOS HEALTH
    • PAREXEL INTERNATIONAL（MA）CORPORATION
    • LGC LIMITED
    • CELERION
    • BIOAGILYTIX

第11章 付録

目次
Product Code: AST 4341

The Healthcare analytical testing services Market is projected to reach USD 12.6 billion by 2029 from USD 7.4 billion in 2024, at a CAGR of 11.2% during the forecast period. The growth of the healthcare analytical testing services market is fueled by increasing demand across industries for quality assurance and regulatory compliance. Challenges in developing precise analytical techniques provide opportunities for service providers, while government initiatives encourage investment and innovation. These factors drive market expansion globally, alongside trends such as outsourcing due to pricing concerns and the development of innovative medicines. Expansion into new locations also boosts demand for specific tests, further driving the need for healthcare analytical testing services.

Scope of the Report
Years Considered for the Study2021-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsType and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America and Middle East Africa

"Biohealthcare analytical testing services segment accounted for a substantial share of the healthcare analytical testing services market, by type in 2023."

The Biohealthcare analytical testing services segment is expected to account for the largest share of 37.1% of the global Healthcare analytical testing services Market in 2023. It is projected to grow at the highest CAGR of 10.7% during the forecast period. The healthcare analytical testing services market is segmented by type into various categories, including bioanalytical testing, physical characterization, method development and validation, stability testing, batch-release testing, raw material testing, microbial testing, genomic services, and environmental monitoring services. In 2023, the biohealthcare analytical testing services segment stood out as the largest, primarily due to its comprehensive offerings tailored to different drug types like vaccines, small molecules, and biologics. This extensive range of services meets the diverse requirements of pharmaceutical and biopharmaceutical companies, thereby driving the segment's substantial market share.

"The cell-based assays segment accounted for the largest share in the healthcare analytical testing services market"

Based on bioanalytical service types type, the market encompasses cell-based assays, virology testing, biomarker testing, immunogenicity and neutralizing antibody testing, pharmacokinetic testing, and other biohealthcare analytical testing services. In 2023, the cell-based assays segment emerged as the market leader. This dominance is attributed to the growing preference for cell-based assays in high-throughput screening, as they offer pertinent in vivo biological insights compared to biochemical assays. This advantage accelerates the drug discovery process, thus contributing to the segment's prominence.

"North America to witness the substantial growth rate during the forecast period."

North America commands the largest share in the healthcare analytical testing services market, outstripping other regions such as Europe, Asia Pacific, Latin America, and the Middle East & Africa. This dominance is primarily fueled by the burgeoning number of biopharmaceutical and pharmaceutical companies based in the United States. Moreover, the US market benefits from the strong foothold of well-established players, which further propels the market's growth trajectory. The region's advanced infrastructure, supportive regulatory environment, and emphasis on research and development also contribute significantly to its leadership position in the global healthcare analytical testing services market.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
  • By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
  • By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, ROW-10%

Key Players in the Healthcare analytical testing services Market

The prominent players in the global healthcare analytical testing services market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Medpace Holdings, Inc. (US), LGC Limited (Cinven) (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), BioAgilytix Labs (US), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), and Syneos Health, INC (US).

Research Coverage:

The report analyzes the Healthcare analytical testing services Market and aims to estimate the market size and future growth potential of various market segments, based on type, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of Market Dynamics (Stringent regulatory landscape, growing focus on analytical testing of bilogics and biomilars, rising investments in pharma and biopharma R & D), restraints (Increasing Preassure on market players due to rising cost and market competition), opportunities (Adoption of new technologies, supporting government initiatives), and challenges (increasing need for improvement of sentsitivity of bioanalytical methods)
  • Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new service launches in the Healthcare analytical testing services market.
  • Market Development: Comprehensive information on the lucrative emerging markets, component, demographics , end-user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKET SEGMENTATION
    • FIGURE 1 MARKETS COVERED
    • 1.2.3 REGIONS COVERED
    • FIGURE 2 REGIONAL SEGMENTATION
    • 1.2.4 YEARS CONSIDERED
  • 1.3 CURRENCY CONSIDERED
  • 1.4 LIMITATIONS
    • 1.4.1 METHODOLOGY-RELATED LIMITATIONS
    • 1.4.2 SCOPE-RELATED LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH METHODOLOGY DESIGN
    • FIGURE 3 RESEARCH DESIGN
    • 2.2.1 SECONDARY RESEARCH
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
    • FIGURE 4 PRIMARY SOURCES
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Insights from primary experts
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION METHODOLOGY
    • FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 8 REVENUE SHARE ANALYSIS: COMPANY ILLUSTRATION
    • FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION
    • FIGURE 10 TOP-DOWN APPROACH
    • FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 12 CAGR PROJECTIONS
  • 2.4 DATA TRIANGULATION PROCEDURE
    • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ESTIMATION
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT ANALYSIS
  • 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 14 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 16 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 17 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF HEALTHCARE ANALYTICAL TESTING SERVICES MARKET

4 PREMIUM INSIGHTS

  • 4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW
    • FIGURE 19 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH
  • 4.2 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE AND COUNTRY (2023)
    • FIGURE 20 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023
  • 4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 CHINA, INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 REGIONAL MIX: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2022-2029)
    • FIGURE 22 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2022-2029)
  • 4.5 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEVELOPED VS. EMERGING ECONOMIES (2024 VS. 2029)
    • FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 24 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Stringent regulatory guidelines
      • 5.2.1.2 Growing focus on analytical testing of biologics & biosimilars
    • TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
      • 5.2.1.3 Increasing outsourcing of analytical testing by pharmaceutical & medical device companies
      • 5.2.1.4 Increasing number of clinical trials
    • FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2004-2024)
    • FIGURE 26 PERCENTAGE OF REGISTERED STUDIES BY LOCATION (AS OF MARCH 08, 2024)
      • 5.2.1.5 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
    • FIGURE 27 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2002-2022
      • 5.2.1.6 Rising acceptance of quality-by-design approach in pharmaceutical research & manufacturing
    • TABLE 3 IMPACT ANALYSIS: DRIVERS
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Increasing pressure on market players due to rising costs and market competition
    • TABLE 4 IMPACT ANALYSIS: RESTRAINTS
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Adoption of new techniques and technologies
      • 5.2.3.2 Growing focus on emerging economies
    • TABLE 5 IMPACT ANALYSIS: OPPORTUNITIES
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of skilled professionals
      • 5.2.4.2 Specific requirements for innovative formulations and medical devices
      • 5.2.4.3 Need to improve sensitivity of bioanalytical methods
    • TABLE 6 IMPACT ANALYSIS: CHALLENGES
  • 5.3 ECOSYSTEM ANALYSIS
    • TABLE 7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ROLE IN ECOSYSTEM
    • FIGURE 28 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 29 VALUE CHAIN ANALYSIS
  • 5.5 CASE STUDY ANALYSIS
    • 5.5.1 UNLOCKING BIOPHARMACEUTICAL DEVELOPMENT POTENTIAL THROUGH OUTSOURCING ANALYTICAL TESTING
    • 5.5.2 REVOLUTIONIZING PHARMACEUTICAL TESTING: A CASE STUDY IN ANALYTICAL TESTING EVOLUTION
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 30 PORTER'S FIVE FORCES ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 BARGAINING POWER OF SUPPLIERS
    • 5.6.3 INTENSITY OF COMPETITIVE RIVALRY
    • 5.6.4 BARGAINING POWER OF BUYERS
    • 5.6.5 THREAT OF SUBSTITUTES
  • 5.7 REGULATORY LANDSCAPE
    • 5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.7.2 REGULATORY ANALYSIS
    • TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS
    • TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES
    • 5.7.3 NORTH AMERICA
    • 5.7.4 EUROPE
    • TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES
    • TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES
    • 5.7.5 ASIA PACIFIC
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 31 REVENUE SHIFT AND NEW POCKETS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
  • 5.9 KEY CONFERENCES & EVENTS, 2024-2025
    • TABLE 18 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.10 INVESTMENT AND FUNDING SCENARIO
    • FIGURE 32 NUMBER OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022
    • FIGURE 33 VALUE OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
    • TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
    • 5.11.2 BUYING CRITERIA
    • FIGURE 35 KEY BUYING CRITERIA FOR END USERS
    • TABLE 20 KEY BUYING CRITERIA FOR END USERS

6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 6.2 BIOANALYTICAL TESTING
    • TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.1 PHARMACOKINETIC & TOXICOKINETIC TESTING
      • 6.2.1.1 Increasing number of clinical trials for drug development to propel growth
    • TABLE 24 PHARMACOKINETIC TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.2 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING
      • 6.2.2.1 Increasing requirement for drug safety approvals to support market growth
    • TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.3 BIOMARKER TESTING
      • 6.2.3.1 Rising need for specialized drug development to drive market
    • TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.4 BIOASSAY TESTING
      • 6.2.4.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth
    • TABLE 27 BIOASSAY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.5 OTHER BIOANALYTICAL TESTING SERVICES
    • TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.3 PHYSICAL CHARACTERIZATION
    • TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.1 LASER PARTICLE SIZE ANALYSIS
      • 6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market
    • TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.2 THERMAL ANALYSIS
      • 6.3.2.1 Advancements in thermal analysis techniques to support growth
    • TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.3 OPTICAL CHARACTERIZATION
      • 6.3.3.1 Growing complexity of biological structures to contribute to growth
    • TABLE 33 OPTICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.4 SURFACE AREA ANALYSIS
      • 6.3.4.1 Growing need for surface analysis to streamline drug development processes to fuel growth
    • TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES
    • TABLE 35 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.4 METHOD DEVELOPMENT & VALIDATION
    • TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION
      • 6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market
    • TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION
      • 6.4.2.1 Rising emphasis on impurity testing to boost market
    • TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.3 STABILITY-INDICATING METHOD VALIDATION
      • 6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth
    • TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.4 CLEANING VALIDATION & METHOD DEVELOPMENT
      • 6.4.4.1 Growing needs to evaluate cleaning practices and ensure complete decontamination to fuel growth
    • TABLE 41 CLEANING VALIDATION & METHOD DEVELOPMENT SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.5 ANALYTICAL STANDARD CHARACTERIZATION
      • 6.4.5.1 Growing importance of analytical standard characterization in drug development to support market
    • TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.6 TECHNICAL CONSULTING
      • 6.4.6.1 Need for regulatory approvals for drug development to drive market
    • TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES
    • TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.5 RAW MATERIAL TESTING
    • TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.5.1 COMPLETE COMPENDIAL TESTING
      • 6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth
    • TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.5.2 CONTAINER TESTING
      • 6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth
    • TABLE 48 CONTAINER TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.5.3 HEAVY METAL TESTING
      • 6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth
    • TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.5.4 WATER CONTENT ANALYSIS
      • 6.5.4.1 Need to check for water content in pharmaceutical products to support growth
    • TABLE 50 WATER CONTENT ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.5.5 OTHER RAW MATERIAL TESTING SERVICES
    • TABLE 51 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.6 BATCH-RELEASE TESTING SERVICES
    • TABLE 52 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.6.1 DISSOLUTION TESTING
      • 6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth
    • TABLE 54 DISSOLUTION TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.6.2 ELEMENTAL IMPURITY TESTING
      • 6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth
    • TABLE 55 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.6.3 DISINTEGRATION TESTING
      • 6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth
    • TABLE 56 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA
    • TABLE 57 DISINTEGRATION TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.6.4 HARDNESS TESTING
      • 6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth
    • TABLE 58 HARDNESS TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.6.5 FRIABILITY TESTING
      • 6.6.5.1 Need to measure resistance of tablets and granules to abrasion or fracture to support market
    • TABLE 59 FRIABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.6.6 OTHER BATCH-RELEASE TESTING SERVICES
    • TABLE 60 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.7 STABILITY TESTING
    • TABLE 61 STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 62 STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.7.1 DRUG SUBSTANCE STABILITY TESTING
      • 6.7.1.1 Regulatory requirements for drug approval to drive market
    • TABLE 63 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.7.2 FORMULATION EVALUATION STABILITY TESTING
      • 6.7.2.1 Need to analyze and predict shelf life of products to drive demand
    • TABLE 64 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.7.3 ACCELERATED STABILITY TESTING
      • 6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth
    • TABLE 65 ACCELERATED STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.7.4 PHOTOSTABILITY TESTING
      • 6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption
    • TABLE 66 PHOTOSTABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.7.5 FORCED DEGRADATION TESTING
      • 6.7.5.1 Regulatory requirements and need for comprehensive stability testing in pharmaceutical industry to boost market
    • TABLE 67 FORCED DEGRADATION TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.7.6 OTHER STABILITY TESTING SERVICES
    • TABLE 68 OTHER STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.8 MICROBIAL TESTING
    • TABLE 69 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.8.1 MICROBIAL LIMIT TESTING
      • 6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption
    • TABLE 71 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING
    • TABLE 72 MICROBIAL LIMIT TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.8.2 VIROLOGY TESTING
      • 6.8.2.1 Increasing outbreaks of viral diseases to drive market
    • TABLE 73 VIROLOGY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.8.3 STERILITY TESTING
      • 6.8.3.1 Rising development of parenteral preparations and immunological products to drive market
    • TABLE 74 STERILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.8.4 ENDOTOXIN TESTING
      • 6.8.4.1 Need to standardize procedures and follow regulatory guidelines to support demand
    • TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.8.5 PRESERVATIVE EFFICACY TESTING
      • 6.8.5.1 Need to ensure product safety for product approval to support growth
    • TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.8.6 OTHER MICROBIAL TESTING SERVICES
    • TABLE 77 OTHER MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.9 GENOMIC TESTING SERVICES
    • 6.9.1 NEED TO GAIN INSIGHTS INTO DISEASE MECHANISMS AND TREATMENT RESPONSES TO BOOST MARKET
    • TABLE 78 GENOMIC TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.10 OTHER ANALYTICAL TESTING SERVICES
    • TABLE 79 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)

7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 80 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 7.2 PHARMACEUTICAL COMPANIES
    • 7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH
    • FIGURE 36 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2020-2022
    • TABLE 81 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • 7.3 BIOPHARMACEUTICAL COMPANIES
    • 7.3.1 GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH
    • TABLE 82 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • 7.4 MEDICAL DEVICE COMPANIES
    • 7.4.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH
    • TABLE 83 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • 7.5 HOSPITALS & CLINICS
    • 7.5.1 GROWING PREVALENCE OF CHRONIC DISEASES TO FAVOR MARKET GROWTH
    • TABLE 84 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
  • 7.6 FORENSIC LABS
    • 7.6.1 GROWING USE OF ANALYTICAL TESTING IN FORENSIC LABS TO BOOST MARKET GROWTH
    • TABLE 85 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR FORENSIC LABS, BY REGION, 2022-2029 (USD MILLION)
  • 7.7 COSMETIC & NUTRACEUTICAL COMPANIES
    • 7.7.1 STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET
    • TABLE 86 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR COSMETIC & NUTRACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION)

8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • FIGURE 37 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT
    • TABLE 87 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 8.2 NORTH AMERICA
    • 8.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 38 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
    • TABLE 88 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 89 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 90 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 91 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 92 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 93 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 94 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 95 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 96 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 97 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 8.2.2 US
      • 8.2.2.1 High number of pre-registration drugs in pipeline to drive market
    • FIGURE 39 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2021)
    • TABLE 98 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 99 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 100 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 101 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 102 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 103 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 104 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 105 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.2.3 CANADA
      • 8.2.3.1 Presence of well-established CROs to support market growth
    • FIGURE 40 CANADA: ONGOING CLINICAL TRIALS, BY THERAPEUTIC AREA (2023)
    • TABLE 106 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 107 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 108 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 109 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 110 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 111 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 112 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 113 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 8.3 EUROPE
    • 8.3.1 EUROPE: RECESSION IMPACT
    • TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 115 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 116 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 117 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 118 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 119 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 120 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 121 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 122 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 123 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 8.3.2 GERMANY
      • 8.3.2.1 Government support and flexible labor laws make Germany favorable location for clinical trials
    • TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Favorable government regulations to drive market
    • TABLE 132 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 133 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 134 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 135 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 136 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 137 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 138 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 139 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.3.4 UK
      • 8.3.4.1 Investments by pharmaceutical sponsors for drug discovery services to support growth
    • TABLE 140 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 141 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 142 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 143 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 144 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 145 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 146 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 147 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.3.5 ITALY
      • 8.3.5.1 Low drug approval time to support market growth
    • TABLE 148 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 149 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 150 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 151 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 152 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 153 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 154 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 155 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.3.6 SWITZERLAND
      • 8.3.6.1 Large and growing pharma production volume to drive demand for analytical testing services
    • TABLE 156 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 157 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 158 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 159 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 160 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 161 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 162 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 163 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.3.7 SPAIN
      • 8.3.7.1 Rising R&D expenditure to boost growth
    • TABLE 164 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 165 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 166 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 167 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 168 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 169 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 170 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 171 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.3.8 REST OF EUROPE
    • TABLE 172 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 173 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 174 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 175 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 176 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 177 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 178 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 179 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • 8.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 41 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT
    • TABLE 180 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 181 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 182 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 183 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 184 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 185 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 186 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 187 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 188 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 189 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 8.4.2 CHINA
      • 8.4.2.1 Low manufacturing cost of medicines to drive demand
    • TABLE 190 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 191 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 192 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 193 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 194 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 195 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 196 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 197 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.4.3 JAPAN
      • 8.4.3.1 Rising geriatric population to support market growth
    • TABLE 198 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 199 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 200 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 201 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 202 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 203 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 204 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 205 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.4.4 INDIA
      • 8.4.4.1 Increasing number of clinical trials to drive market
    • TABLE 206 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 207 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 208 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 209 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 210 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 211 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 212 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 213 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.4.5 AUSTRALIA
      • 8.4.5.1 Large number of research institutes make Australia favorable location for drug discovery
    • TABLE 214 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 215 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 216 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 217 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 218 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 219 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 220 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 221 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.4.6 SOUTH KOREA
      • 8.4.6.1 Growth in clinical trial activities to propel market
    • TABLE 222 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 223 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 224 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 225 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 226 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 227 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 228 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 229 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.4.7 REST OF ASIA PACIFIC
    • TABLE 230 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 231 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 232 REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 233 REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 234 REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 235 REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 236 REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 237 REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 8.5 LATIN AMERICA
    • 8.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 238 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 239 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 240 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 241 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 242 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 243 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 244 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 245 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 246 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 247 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 8.5.2 BRAZIL
      • 8.5.2.1 Rising adoption of emerging medical technologies to drive market
    • TABLE 248 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 249 BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 250 BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 251 BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 252 BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 253 BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 254 BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 255 BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.5.3 MEXICO
      • 8.5.3.1 Government initiatives and robust supply to drive market
    • TABLE 256 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 257 MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 258 MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 259 MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 260 MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 261 MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 262 MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 263 MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.5.4 REST OF LATIN AMERICA
    • TABLE 264 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 265 REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 266 REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 267 REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 268 REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 269 REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 270 REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 271 REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 272 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 273 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 274 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 275 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 276 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 277 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 278 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 279 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 280 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 281 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 8.6.2 GCC
      • 8.6.2.1 Supportive government initiatives to aid market growth
    • TABLE 282 GCC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 283 GCC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 284 GCC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 285 GCC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 286 GCC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 287 GCC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 288 GCC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 289 GCC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 8.6.3 REST OF MIDDLE EAST & AFRICA
    • TABLE 290 REST OF MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 291 REST OF MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 292 REST OF MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 293 REST OF MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 294 REST OF MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 295 REST OF MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 296 REST OF MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 297 REST OF MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
  • 9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 42 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: STRATEGIES ADOPTED
  • 9.3 REVENUE SHARE ANALYSIS
    • FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS (2018-2022)
  • 9.4 MARKET SHARE ANALYSIS
    • FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 298 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEGREE OF COMPETITION
  • 9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 9.5.1 STARS
    • 9.5.2 PERVASIVE PLAYERS
    • 9.5.3 EMERGING LEADERS
    • 9.5.4 PARTICIPANTS
    • FIGURE 45 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 9.5.5 COMPANY FOOTPRINT
      • 9.5.5.1 Overall footprint
    • FIGURE 46 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: OVERALL FOOTPRINT
      • 9.5.5.2 Service footprint
    • TABLE 299 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE FOOTPRINT
      • 9.5.5.3 End-user footprint
    • TABLE 300 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: END-USER FOOTPRINT
      • 9.5.5.4 Regional footprint
    • TABLE 301 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: REGIONAL FOOTPRINT
  • 9.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
    • 9.6.1 PROGRESSIVE COMPANIES
    • 9.6.2 DYNAMIC COMPANIES
    • 9.6.3 RESPONSIVE COMPANIES
    • 9.6.4 STARTING BLOCKS
    • FIGURE 47 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
    • 9.6.5 COMPETITIVE BENCHMARKING
    • TABLE 302 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 303 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • 9.7 VALUATION AND FINANCIAL METRICS OF HEALTHCARE ANALYTICAL TESTING SERVICE VENDORS
    • FIGURE 48 EV/EBITDA OF KEY VENDORS
  • 9.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
    • FIGURE 49 BRAND/PRODUCT COMPARATIVE ANALYSIS OF KEY PLAYERS, BY SERVICE TYPE
    • 9.8.1 EUROFINS SCIENTIFIC
    • 9.8.2 WUXI APPTEC
    • 9.8.3 CHARLES RIVER LABORATORIES
    • 9.8.4 SGS S.A.
    • 9.8.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
  • 9.9 COMPETITIVE SCENARIO
    • 9.9.1 SERVICE LAUNCHES
    • TABLE 304 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020-MARCH 2024
    • 9.9.2 DEALS
    • TABLE 305 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEALS, JANUARY 2020-MARCH 2024
    • TABLE 306 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: EXPANSIONS, JANUARY 2020-MARCH 2024

10 COMPANY PROFILES

  • 10.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 10.1.1 EUROFINS SCIENTIFIC
    • TABLE 307 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
    • FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • TABLE 308 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 309 EUROFINS SCIENTIFIC: DEALS
    • 10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 310 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
    • FIGURE 51 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
    • TABLE 311 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 312 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS
    • TABLE 313 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS
    • 10.1.3 WUXI APPTEC
    • TABLE 314 WUXI APPTEC: COMPANY OVERVIEW
    • FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT (2022)
    • TABLE 315 WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 316 WUXI APPTEC: SERVICE LAUNCHES
    • TABLE 317 WUXI APPTEC: DEALS
    • TABLE 318 WUXI APPTEC: EXPANSIONS
    • 10.1.4 CHARLES RIVER LABORATORIES
    • TABLE 319 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
    • FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
    • TABLE 320 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 321 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES
    • TABLE 322 CHARLES RIVER LABORATORIES: DEALS
    • 10.1.5 SGS S.A.
    • TABLE 323 SGS S.A.: COMPANY OVERVIEW
    • FIGURE 54 SGS S.A.: COMPANY SNAPSHOT (2023)
    • TABLE 324 SGS S.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 325 SGS S.A.: DEALS
    • TABLE 326 SGS S.A.: OTHER DEVELOPMENTS
    • 10.1.6 THERMO FISHER SCIENTIFIC INC.
    • TABLE 327 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • TABLE 328 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 329 THERMO FISHER SCIENTIFIC INC.: DEALS
    • TABLE 330 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
    • 10.1.7 MEDPACE, INC.
    • TABLE 331 MEDPACE, INC.: COMPANY OVERVIEW
    • FIGURE 56 MEDPACE, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 332 MEDPACE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 10.1.8 SARTORIUS AG
    • TABLE 333 SARTORIUS AG: COMPANY OVERVIEW
    • FIGURE 57 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • TABLE 334 SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 335 SARTORIUS AG: DEALS
    • 10.1.9 INTERTEK GROUP PLC
    • TABLE 336 INTERTEK GROUP PLC: COMPANY OVERVIEW
    • FIGURE 58 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2022)
    • TABLE 337 INTERTEK GROUP PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 338 INTERTEK GROUP PLC: DEALS
    • TABLE 339 INTERTEK GROUP PLC: EXPANSIONS
    • 10.1.10 MERCK KGAA
    • TABLE 340 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • TABLE 341 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 342 MERCK KGAA: SERVICE LAUNCHES
    • TABLE 343 MERCK KGAA: DEALS
    • TABLE 344 MERCK KGAA: EXPANSIONS
    • TABLE 345 MERCK KGAA: OTHER DEVELOPMENTS
    • 10.1.11 SOURCE BIOSCIENCE
    • TABLE 346 SOURCE BIOSCIENCE: COMPANY OVERVIEW
    • FIGURE 60 SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2022)
    • TABLE 347 SOURCE BIOSCIENCE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 348 SOURCE BIOSCIENCE: SERVICE LAUNCHES
    • TABLE 349 SOURCE BIOSCIENCE: EXPANSIONS
    • 10.1.12 ICON PLC
    • TABLE 350 ICON PLC: COMPANY OVERVIEW
    • FIGURE 61 ICON PLC: COMPANY SNAPSHOT (2022)
    • TABLE 351 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 352 ICON PLC: DEALS
    • 10.1.13 ALS
    • TABLE 353 ALS: COMPANY OVERVIEW
    • FIGURE 62 ALS: COMPANY SNAPSHOT (2022)
    • TABLE 354 ALS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 355 ALS: DEALS
    • 10.1.14 FRONTAGE LABORATORIES, INC.
    • TABLE 356 FRONTAGE LABORATORIES, INC.: COMPANY OVERVIEW
    • FIGURE 63 FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 357 FRONTAGE LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 358 FRONTAGE LABORATORIES, INC.: DEALS
    • TABLE 359 FRONTAGE LABORATORIES, INC.: OTHER DEVELOPMENTS
    • 10.1.15 STERIS
    • TABLE 360 STERIS: COMPANY OVERVIEW
    • FIGURE 64 STERIS: COMPANY SNAPSHOT (2023)
    • TABLE 361 STERIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 10.1.16 IQVIA INC.
    • TABLE 362 IQVIA INC.: COMPANY OVERVIEW
    • FIGURE 65 IQVIA INC.: COMPANY SNAPSHOT (2023)
    • TABLE 363 IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 364 IQVIA INC.: OTHER DEVELOPMENTS
    • 10.1.17 ELEMENT MATERIALS TECHNOLOGY
    • TABLE 365 ELEMENT MATERIALS TECHNOLOGY: COMPANY OVERVIEW
    • TABLE 366 ELEMENT MATERIALS TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 367 ELEMENT MATERIALS TECHNOLOGY: SERVICE LAUNCHES
    • TABLE 368 ELEMENT MATERIALS TECHNOLOGY: DEALS
    • TABLE 369 ELEMENT MATERIALS TECHNOLOGY: EXPANSIONS
    • 10.1.18 PACE ANALYTICAL SERVICES
    • TABLE 370 PACE ANALYTICAL SERVICES: COMPANY OVERVIEW
    • TABLE 371 PACE ANALYTICAL SERVICES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 372 PACE ANALYTICAL SERVICES: DEALS
    • TABLE 373 PACE ANALYTICAL SERVICES: OTHER DEVELOPMENTS
    • 10.1.19 ALMAC GROUP
    • TABLE 374 ALMAC GROUP: COMPANY OVERVIEW
    • TABLE 375 ALMAC GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 376 ALMAC GROUP: SERVICE LAUNCHES
    • TABLE 377 ALMAC GROUP: EXPANSIONS
    • 10.1.20 PHARMARON
    • TABLE 378 PHARMARON: COMPANY OVERVIEW
    • TABLE 379 PHARMARON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 380 PHARMARON: DEALS
  • 10.2 OTHER PLAYERS
    • 10.2.1 SYNEOS HEALTH
    • TABLE 381 SYNEOS HEALTH: COMPANY OVERVIEW
    • 10.2.2 PAREXEL INTERNATIONAL (MA) CORPORATION
    • TABLE 382 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW
    • 10.2.3 LGC LIMITED
    • TABLE 383 LGC LIMITED: COMPANY OVERVIEW
    • 10.2.4 CELERION
    • TABLE 384 CELERION: COMPANY OVERVIEW
    • 10.2.5 BIOAGILYTIX
    • TABLE 385 BIOAGILYTIX: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS